How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?
Perazella
Mark A
MA
D003287:Contrast Media / Q000009:adverse effects*; D005355:Fibrosis; D005682:Gadolinium; D019786:Gadolinium DTPA / Q000009:adverse effects; D006571:Heterocyclic Compounds / Q000009:adverse effects*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000473:pathology / Q000628:therapy*; D018810:Magnetic Resonance Angiography; D008279:Magnetic Resonance Imaging; D009942:Organometallic Compounds / Q000009:adverse effects*; D018579:Patient Selection; D006435:Renal Dialysis; D018570:Risk Assessment; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology; D013997:Time Factors
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; C064925:gadodiamide; D005682:Gadolinium; D019786:Gadolinium DTPA; C112666:gadoversetamide